HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747).

Abstract
Selective, nonpeptidic delta opioid receptor agonists have been the subject of great interest as potential novel analgesic agents. The discoveries of BW373U86 (1) and SNC80 (2) contributed to the rapid expansion of research in this field. However, poor drug-like properties and low therapeutic indices have prevented clinical evaluation of these agents. Doses of 1 and 2 similar to those required for analgesic activity produce convulsions in rodents and nonhuman primates. Recently, we described a novel series of potent, selective, and orally bioavailable delta opioid receptor agonists. The lead derivative, ADL5859 (4), is currently in phase II proof-of-concept studies for the management of pain. Further structure activity relationship exploration has led to the discovery of ADL5747 (36), which is approximately 50-fold more potent than 4 in an animal model of inflammatory pain. On the basis of its favorable efficacy, safety, and pharmacokinetic profile, 36 was selected as a clinical candidate for the treatment of pain.
AuthorsBertrand Le Bourdonnec, Rolf T Windh, Lara K Leister, Q Jean Zhou, Christopher W Ajello, Minghua Gu, Guo-Hua Chu, Paul A Tuthill, William M Barker, Michael Koblish, Daniel D Wiant, Thomas M Graczyk, Serge Belanger, Joel A Cassel, Marina S Feschenko, Bernice L Brogdon, Steven A Smith, Michael J Derelanko, Steve Kutz, Patrick J Little, Robert N DeHaven, Diane L DeHaven-Hudkins, Roland E Dolle
JournalJournal of medicinal chemistry (J Med Chem) Vol. 52 Issue 18 Pg. 5685-702 (Sep 24 2009) ISSN: 1520-4804 [Electronic] United States
PMID19694468 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Analgesics
  • Benzamides
  • Benzopyrans
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Ether-A-Go-Go Potassium Channels
  • N,N-diethyl-3-hydroxy-4-(spiro(chromene-2,4'-piperidine)-4-yl)benzamide
  • Receptors, Opioid, delta
  • Spiro Compounds
Topics
  • Analgesics (administration & dosage, chemistry, pharmacology, therapeutic use)
  • Animals
  • Benzamides (administration & dosage, chemistry, pharmacology, therapeutic use)
  • Benzopyrans (administration & dosage, chemistry, pharmacology, therapeutic use)
  • CHO Cells
  • Clinical Trials as Topic
  • Cricetinae
  • Cricetulus
  • Crystallography, X-Ray
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Dogs
  • Dose-Response Relationship, Drug
  • Drug Discovery
  • Ether-A-Go-Go Potassium Channels (antagonists & inhibitors)
  • Humans
  • Hyperalgesia (drug therapy)
  • Male
  • Pain (drug therapy)
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Opioid, delta (agonists)
  • Spiro Compounds (administration & dosage, chemistry, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: